Regulatory agencies in both the UK and Belgium have started to review applications from pharmaceutical companies for exploratory clinical trials which are designed to generate information on the safety in man of new compounds before the traditional Phase 1 studies begin, according to speakers at a meeting of the Drug Information Association in Barcelona, Spain on 5 March 2008.
